[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1684790A2 - Preparations homogenes de proteines chimeres - Google Patents

Preparations homogenes de proteines chimeres

Info

Publication number
EP1684790A2
EP1684790A2 EP04800480A EP04800480A EP1684790A2 EP 1684790 A2 EP1684790 A2 EP 1684790A2 EP 04800480 A EP04800480 A EP 04800480A EP 04800480 A EP04800480 A EP 04800480A EP 1684790 A2 EP1684790 A2 EP 1684790A2
Authority
EP
European Patent Office
Prior art keywords
residue
polypeptide
mutation
chimeric protein
factor vila
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04800480A
Other languages
German (de)
English (en)
Other versions
EP1684790A4 (fr
Inventor
Patrick W. Trown
Michael I. Sherman
Kirk Dornbush
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iconic Therapeutics Inc
Original Assignee
Iconic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iconic Therapeutics Inc filed Critical Iconic Therapeutics Inc
Publication of EP1684790A2 publication Critical patent/EP1684790A2/fr
Publication of EP1684790A4 publication Critical patent/EP1684790A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the invention relates to the field of immunotherapy. More particularly, it relates to the use of chimeric proteins comprising a targeting moiety and a cytolytic moiety.
  • PNV pathological neovasculature
  • AMD age-related macular degeneration
  • TF tissue factor
  • the Icon is composed of factor VII (fVII), the natural ligand forTF, at the N-terminus of the Icon molecule, fused to the Fc domain of an IgGl Ig at the C-terminus of the Icon molecule.
  • the Icon functions similarly to an anti-TF antibody, but with considerably higher affinity than can be achieved with an anti-TF antibody.
  • the TF-Icon complex is believed to activate a potent cytolytic immune attack mediated by natural killer cells and complement (Hsu, Z., Sun, Y., and Garen, A. (1999) Proc. Natl. Acad. Sci. USA96, 81612-8166).
  • Native Factor VII is a zymogen. Typically, in instances of blood vessel damage, Factor VII initiates the coagulation process by binding to TF; this binding promotes cleavage of Factor VII between positions 152 and 153 to generate an activated protease, Factor Vila (fVIIa), which continues the coagulation cascade.
  • Jurlander et al Jurlander, B., Thim, L., Klausen, N.K., Persson,E., Kjalke, M., Rexen, P., Jergensen, T., Ostergaard, P.B., Erhardtsen, E. & Bjorn, S.E. (2001) Sem.
  • Thrombosis Hemostasis 27, 373-383 have demonstrated that Factor VII is susceptible to this cleavage during purification under certain conditions.
  • Factor VII and Factor Vila are susceptible to an additional cleavage, between positions 38 and 39, that results in a much reduced affinity for TF (Sakai, T., Lund-Hansen, T., Thim, L. & Kisiel, W. (1990) J. Biol. Chem. 265, 1890-1894).
  • a chimeric protein comprises a first and a second polypeptide.
  • the first polypeptide is a Factor VII or Factor Vila polypeptide and the second polypeptide is an Fc region of a human immunoglobulin IgGl.
  • the Factor VII or Factor Vila polypeptide contains at least one mutant residue that prevents proteolytic cleavage between residues 38 and 39 or between residues 152 and 153.
  • a method is provided of treating a patient having a disease associated with neovascularization.
  • An effective amount of a chimeric protein is administered to the patient.
  • the chimeric protein comprises a first and a second polypeptide.
  • the first polypeptide is a Factor VII or Factor Vila polypeptide and the second polypeptide is an Fc region of a human immunoglobulin IgGl .
  • the Factor VII or Factor Vila polypeptide contains at least one mutant residue that prevents proteolytic cleavage between residues 38 and 39 or between residues 152 and 153. Symptoms of the disease are ameliorated by the chimeric protein.
  • an expression vector encodes a secreted form of a chimeric protein.
  • the chimeric protein comprises a first and a second polypeptide.
  • the first polypeptide is a Factor VII or Factor Vila polypeptide and the second polypeptide is an Fc region of a human immunoglobulin IgGl.
  • the Factor VII or Factor Vila polypeptide contains at least one mutant residue, which prevents proteolytic cleavage between residues 38 and 39 or between residues 152 and 153.
  • a method for treating a patient having disease associated with neovascularization An effective amount of an expression vector is administered to the patient.
  • the expression vector encodes a secreted form of a chimeric protein comprising a first and a second polypeptide.
  • the first polypeptide is a Factor VII or Factor Vila polypeptide and the second polypeptide is an Fc region of a human immunoglobulin IgGl.
  • the Factor VII or Factor Vila polypeptide contains at least one mutant residue, which prevents proteolytic cleavage between residues 38 and 39 or between residues 152 and 153. Symptoms of the disease are ameliorated by the administration of the expression vector.
  • a chimeric protein comprises a first and a second polypeptide.
  • the first polypeptide is a Factor Vila polypeptide and the second polypeptide is an Fc region of a human immunoglobulin IgGl.
  • the Factor Vila polypeptide contains at least one mutant residue which reduces blood coagulation activity relative to wild-type Factor Vila.
  • Desirable chimeras of Factor VII or Factor Vila and the Fc region of immunoglobulin IgGl bind with high affinity to Tissue Factor (TF), do not initiate the clotting cascade, and are resistant to degradation in the body. Mutations in Factor VII that prevent proteolytic cleavage enhance these desirable characteristics. In particular, mutations that prevent the proteolytic cleavage between amino acid residues 152 and 153 of Factor VII markedly reduce the ability of the chimeric protein to initiate the coagulation cascade while the chimeric protein retains the ability to bind with high affinity to TF.
  • chimeric proteins with mutations that prevent the proteolytic cleavage between amino acids 38 and 39 maintain the high affinity binding to Tissue Factor, which is lost after that cleavage occurs. Both of these types of mutations prevent proteolytic cleavages of the chimeric protein, thus maintaining a homogeneous, therapeutically active species. These mutations contribute to improved storage stability as well as to increased half-life in the body.
  • any mutation of Factor VII can be used which prevents or reduces proteolytic cleavage between residues 38 and 39 or between residues 152 and 153.
  • Such mutations include but are not limited to mutations in codons 38 and 152.
  • these residues are lysine and arginine, respectively.
  • Alanine mutations can be used to substitute for these residues and abolish cleavage.
  • Substitutions for the arginine at residue 152 with glutamate or glutamine residues have also been found to be effective.
  • Other residues that impact either of the proteolytic cleavage sites, e.g., due to steric hindrance, can also be used.
  • Assays for testing for the cleavage are well known in the art.
  • a simple assay employs the use of SDS-polyacrylamide gel electrophoresis to analyze samples that have been reduced to disrupt intermolecular and intramolecular bonds.
  • the size of the products readily indicates whether cleavage has occurred or not, and if a cleavage has occurred, whether it is between residues 38 and 39 or between residues 152 and 153 or both.
  • the mutations can be used singly or in combinations with each other. Moreover, they can be used in combinations with other beneficial mutations.
  • the chimeric proteins may also contain mutations in the active site of the Factor VII of Factor Vila polypeptide. Such mutations include, but are not limited to those at residues 341 and 344 of Factor VII or Factor Vila.
  • the Fc portion of the chimeric protein may contain beneficial mutations that improve the properties of the protein.
  • certain mutations at two residues of the IgG molecule, K326 and E333 increase its complement-dependent cytotoxicity activity by increasing binding to complement constituent Clq. See Idusogie et al. (2001) J. Immunol. 166, 2571-2572. Similar mutations may be used for the same purpose within the Fc portion of the chimeric protein. Such mutations can be used in combination with other mutations in the Factor VII or Factor Vila polypeptide.
  • Mutations can be introduced into a coding sequence for a chimeric protein using any technique known in the art. Preferably a site-directed mutagenesis technique is used to provide a precise mutation. Alternatively, a random mutagenesis technique is used, coupled with an assay for distinguishing between proteolysis-sensitive and proteolysis-resistant molecules.
  • Chimeric proteins of the invention comprise a first and a second polypeptide.
  • the first polypeptide is a Factor VII or Factor Vila polypeptide and the second polypeptide is an Fc region of a human immunoglobulin IgGl .
  • the polypeptides may comprise only so much of the full proteins as are necessary for functioning in the chimeric protein. Thus the first polypeptide must have the ability to bind to tissue factor with high affinity. The second polypeptide must have the ability to mediate a complement-dependent cytotoxicity response.
  • the amplified fVII cDNA which contains the leader and coding sequences without a stop codon, can be cloned into the H dIII and f ⁇ m ⁇ I sites of the pcDNA3.1(+) vector (Invitrogen) in- frame with a cDNA encoding the human IgGl Fc domain (Wang, B., Chen, Y., Ayalon, O., Bender, J. & Garen, A. (1999) Proc. Natl. Acad. Sci. USA 96, 1627- 1632).
  • the vector DNA can be amplified in ⁇ B101 competent cells (Life Technologies, Grand Island, NY).
  • Mutations can be introduced into fVII or IgGl cDNA by the procedure described in the QuickChange site-directed mutagenesis manual (Stratagene). Other techniques known in the art for making fusion proteins and introducing mutations can be used as is convenient to the individual artisan.
  • Chimeric proteins of the invention can be administered to a patient having a disease associated with neovascularization such as cancer, macular degeneration, rheumatoid arthritis, diabetic retinopathy, psoriasis, or atherosclerosis. Administration may be local or systemic, depending upon the type of pathological condition involved in the therapy.
  • a disease associated with neovascularization such as cancer, macular degeneration, rheumatoid arthritis, diabetic retinopathy, psoriasis, or atherosclerosis.
  • Administration may be local or systemic, depending upon the type of pathological condition involved in the therapy.
  • the term "patient” includes both humans and other mammalian species; the invention thus has both medical and veterinary applications.
  • chimeric proteins can be constructed using targeting and effector domains derived from the corresponding species.
  • chimeric proteins can be via any method known in the art such as, for example, intravenous, intramuscular, intratumoral, subcutaneous, parenteral intrasynovial, intraocular, intraplaque, or intradermal injection.
  • the chimeric protein can also be delivered to the patient by administration of a polynucleotide molecule which encodes the chimeric protein.
  • a clinician can administer a replication-deficient adenoviral vector, adeno-associated vector, or other viral vector carrying a DNA encoding a secreted form of the chimeric protein.
  • the chimeric proteins or nucleic acids are formulated singly or as combinations of proteins, dispersed or solubilized in a pharmaceutically acceptable carrier.
  • Suitable carriers are known in the art. Preferably they are sterile and nonpyrogenic.
  • compositions or formulations of the invention may include other carriers, adjuvants, stabilizers, preservatives, dispersing agents, and other agents conventional in the art.
  • Therapeutic effects of the chimeric proteins can be further enlianced by administering to the patient any other agents known to have a therapeutic effect on the disease being treated.
  • any other agents known to have a therapeutic effect on the disease being treated As an example, cancer patients frequently respond more favorably to combinations of therapies than to single agent therapy.
  • the chimeric proteins can be administered simultaneously with the other agents or the chimeric proteins and the other agent(s) can be added sequentially.
  • Anti-tumor chimeric proteins can be used for treating a variety of cancers, particularly primary or metastatic solid tumors, including but not limited to melanoma, renal, prostate, breast, ovarian, brain, neuroblastoma, colorectal, head and neck, pancreatic, bladder, and lung cancer.
  • the chimeric proteins may be employed to target the tumor vasculature, particularly vascular endothelial cells, and/or tumor cells.
  • the tumor vasculature offers several advantages for immunotherapy, as follows, (i) Some of the vascular targets, including tissue factor, should be the same for all tumors, (ii) Chimeric proteins targeted to the vasculature do not have to infiltrate a tumor mass in order to reach their targets, (iii) Targeting the tumor vasculature should generate an amplified therapeutic response, because each blood vessel nourishes numerous tumor cells whose viability is dependent on the functional integrity of the vessel, (iv) The vasculature is unlikely to develop resistance to a chimeric protein, because that would require modification of the entire endothelium layer lining a vessel. Unlike previously described antiangiogenic methods designed to prevent new vascular growth, chimeric proteins of the invention cytolytically destroy existing neovasculature.
  • Chimeric proteins of the invention are also effective for treating patients with rheumatoid arthritis, wet macular degeneration, diabetic retinopathy, psoriasis, atherosclerosis, and other diseases associated with neovascularization.
  • Administration of a chimeric protein targeted to tissue factor by a mutated human Factor VII or Factor Vila, that is conjugated to the Fc domain of an IgGl immunoglobulin can generate a cytolytic immune response against the vascular endothelial cells that invade the synovium in rheumatoid arthritis and express tissue factor.
  • Factor VII chimeric proteins can also be effective for treating wet macular degeneration or diabetic retinopathy because of the extensive neovascularization in those pathologic conditions.
  • Chimeric proteins of the invention can also be effective for the treatment of atherosclerosis by generating a cytolytic immune response against cells expressing tissue factor in plaques.
  • chimeric proteins of the invention can suppress the excess proliferation of skin cells in psoriasis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Cette invention concerne des formes variantes de protéines chimères comprenant une fraction de facteur VII et une région Fe de fraction IgG1 qui présentent des propriétés améliorées. Ces variants sont plus résistants à la dégradation protéolytique. Ainsi, ces préparations de formes variants sont plus homogènes et ont une demi-vie plus longue. Ces formes variantes sont utilisées dans le traitement du cancer, de l'athérosclérose, du psoriasis, de la rétinopathie diabétique, de la forme humide de la dégénérescence maculaire, et de la polyarthrite rhumatoïde.
EP04800480A 2003-11-18 2004-11-10 Preparations homogenes de proteines chimeres Withdrawn EP1684790A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52064403P 2003-11-18 2003-11-18
PCT/US2004/035517 WO2005051289A2 (fr) 2003-11-18 2004-11-10 Preparations homogenes de proteines chimeres

Publications (2)

Publication Number Publication Date
EP1684790A2 true EP1684790A2 (fr) 2006-08-02
EP1684790A4 EP1684790A4 (fr) 2008-04-30

Family

ID=34632753

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04800480A Withdrawn EP1684790A4 (fr) 2003-11-18 2004-11-10 Preparations homogenes de proteines chimeres

Country Status (5)

Country Link
US (1) US20080193441A1 (fr)
EP (1) EP1684790A4 (fr)
JP (1) JP2007511604A (fr)
CA (1) CA2546580A1 (fr)
WO (1) WO2005051289A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3002012A1 (fr) * 2003-05-06 2016-04-06 Biogen Hemophilia Inc. Coagulation des protéines chimériques de facteur fc pour traiter l'hémophilie
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20100268055A1 (en) * 2007-07-19 2010-10-21 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Self-Anchoring MEMS Intrafascicular Neural Electrode
BRPI0815416A2 (pt) * 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
MX2011008094A (es) 2009-02-03 2012-02-13 Amunix Operating Inc Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos.
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
WO2011028344A2 (fr) * 2009-08-25 2011-03-10 Amunix Operating Inc. Compositions d'antagonistes des récepteurs d'interleukine-1 et leurs procédés de préparation et d'utilisation
DK2591099T3 (da) * 2010-07-09 2021-02-15 Bioverativ Therapeutics Inc Kimære koagulationsfaktorer
JP6383666B2 (ja) 2012-02-15 2018-08-29 バイオベラティブ セラピューティクス インコーポレイテッド 組換え第ｖｉｉｉ因子タンパク質
HRP20221531T1 (hr) 2012-02-15 2023-02-17 Bioverativ Therapeutics Inc. Pripravci faktora viii i postupci dobivanja i korištenja istih
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
KR20180034518A (ko) * 2015-07-22 2018-04-04 아이코닉 테라퓨틱스, 인코포레이티드 혈관신생 및 신혈관형성 관련 장애를 치료하는 방법
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
WO2017083791A1 (fr) * 2015-11-13 2017-05-18 Iconic Therapeutics, Inc. Procédés et compositions de traitement de troubles associés à la néovascularisation pathologique
US20190153119A1 (en) * 2016-04-14 2019-05-23 Iconic Therapeutics, Inc. Compositions and methods for treating disorders associated with neovascularization
EP3573641A4 (fr) * 2017-01-25 2020-11-11 Iconic Therapeutics, Inc. Procédés de traitement de troubles associés à l'angiogenèse et à la néovascularisation
CN112512555A (zh) 2018-05-18 2021-03-16 比奥维拉迪维治疗股份有限公司 治疗血友病a的方法
WO2021030787A1 (fr) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Polypeptides de facteur vii modifiés pour une administration sous-cutanée et un traitement à la demande

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288629A (en) * 1990-01-29 1994-02-22 Zymogenetics, Inc. DNA sequence encoding Factor VII with an amino acid substitution at Avg-152
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
WO2000042072A2 (fr) * 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
WO2001002439A1 (fr) * 1999-07-01 2001-01-11 Yale University Immunoconjugues cibles neovasculaires

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
US20040110929A1 (en) * 2002-07-12 2004-06-10 Bjorn Soren E. TF binding compound

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5288629A (en) * 1990-01-29 1994-02-22 Zymogenetics, Inc. DNA sequence encoding Factor VII with an amino acid substitution at Avg-152
WO2000042072A2 (fr) * 1999-01-15 2000-07-20 Genentech, Inc. Variants polypeptidiques ayant une fonction effectrice alteree
WO2001002439A1 (fr) * 1999-07-01 2001-01-11 Yale University Immunoconjugues cibles neovasculaires

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005051289A2 *

Also Published As

Publication number Publication date
WO2005051289A2 (fr) 2005-06-09
WO2005051289A3 (fr) 2005-12-22
US20080193441A1 (en) 2008-08-14
CA2546580A1 (fr) 2005-06-09
EP1684790A4 (fr) 2008-04-30
JP2007511604A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
US20080193441A1 (en) Homogeneous Preparations of Chimeric Protein
JP3559559B2 (ja) 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
KR100188302B1 (ko) 활성화피브린용해성과항-혈전성단백질
JP6571735B2 (ja) 止血を調節する組成物および方法
JP4451514B2 (ja) 血液凝固第ｖｉｉ因子改変体
JPH05500161A (ja) 抗凝固剤タンパク質
PL204888B1 (pl) Wariant polipeptydu czynnika VII, konstrukcja kwasu nukleinowego, rekombinowana komórka gospodarza, zwierzę transgeniczne, sposób wytwarzania wariantu polipeptydu czynnika VII, kompozycja farmaceutyczna i zastosowanie wariantu polipeptydu czynnika VII
EP2760887B1 (fr) Compositions et procédés pour moduler l'homéostasie
JP3469247B2 (ja) 組換えリボヌクレアーゼタンパク質
WO2008083615A1 (fr) Complexes comprenant de l'angiostatine et ses fragments, leurs procédés de préparation et leurs utilisations
BG107613A (bg) Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена
JP3270462B2 (ja) ハイブリッドプロテインｃ
IE910611A1 (en) Vectors and compounds for expression of glycosylation¹mutants of human protein c
JP7236446B2 (ja) コア－シェル構造のマイクロ粒子を有効成分として含む血液凝固因子遺伝子発現増加用組成物
JP4848270B2 (ja) トロンビン誘導体、およびそれを含有する医薬組成物
KR20130099027A (ko) 혈전용해 및 응고억제 특성을 갖는 단백질 융합 구조물
EP1863910A1 (fr) Proteines de fusion activatrices du plasminogene cible utilisees en tant qu agents thrombolytiques
US20060147441A1 (en) Plasminogen fragment having activity to inhibit tumor metastasis and growth and process for preparing same technical field
JPH0595786A (ja) 変異ヒトプロウロキナーゼ
Huang et al. A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model
EP1268783B9 (fr) Propriétés anti-angiogéniques de la proteine matin et fragments et variants de celui-ci
JPH04210700A (ja) 組換ヒトトロンボモジュリン誘導体
EP1041999A1 (fr) Chimeres et conjugues polypeptidiques thrombogenes presentant une activite dependant de l'association avec l'endothelium vasculaire tumoral
JP3806471B2 (ja) 腫瘍転移増殖抑制効果を有するプラスミノーゲン断片および該断片の調製方法
EP1268798A2 (fr) Proprietes anti-angiogenes et anti-tumorales de la vascostatine et d'autres domaines nidogenes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060512

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20080331

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/08 20060101ALI20080325BHEP

Ipc: C07K 16/00 20060101ALI20080325BHEP

Ipc: A01N 43/04 20060101ALI20080325BHEP

Ipc: A61P 35/00 20060101ALI20080325BHEP

Ipc: A61K 38/16 20060101AFI20060519BHEP

Ipc: A61K 39/40 20060101ALI20080325BHEP

Ipc: A61K 39/42 20060101ALI20080325BHEP

Ipc: A61P 27/00 20060101ALI20080325BHEP

Ipc: A61K 39/00 20060101ALI20080325BHEP

Ipc: A61K 39/395 20060101ALI20080325BHEP

17Q First examination report despatched

Effective date: 20081002

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090415